SCHEMBL25859547

SCHEMBL25859547

C=C(OCC)c1ccn(C(C)C)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.34
ADORA1 P30542 4/20 0.34
ADORA2A P29274 3/20 0.34
LMNA P02545 3/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HPGD P15428 2/20 0.32
MEN1 O00255 1/20 0.32
DYRK1A Q13627 1/20 0.31
MAPT P10636 2/20 0.31
ALDH1A1 P00352 2/20 0.31
CYP1A2 P05177 3/20 0.31
NLRP3 Q96P20 1/20 0.30
TSHR P16473 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
CYP3A4 P08684 2/20 0.30
GABRA1 P14867 2/20 0.30
GABRB2 P47870 2/20 0.30
CYP11B1 P15538 2/20 0.30
CYP11B2 P19099 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1058997 0.81 CYP1A2 (0.49) ADORA3ADORA1ADORA2ALMNASMN1; SMN2
SCHEMBL20759134 0.78 DYRK1A (0.33) DYRK1A
SCHEMBL25859549 0.74 DYRK1A (0.35) ADORA1ADORA2ADYRK1A
SCHEMBL25859581 0.71 DYRK1A (0.33) DYRK1A
SCHEMBL28111818 0.71 KDM5A (0.35) LMNAKMT2ASMN1; SMN2HPGDMEN1
SCHEMBL10026473 0.68 MME (0.39) KMT2ASMN1; SMN2HPGDMEN1DYRK1A
SCHEMBL17065274 0.68 KDM5A (0.37) ADORA1ADORA2ALMNAKMT2ASMN1; SMN2
SCHEMBL23234117 0.68 CYP1A2 (0.53) LMNAKMT2ASMN1; SMN2HPGDMAPT
SCHEMBL1431340 0.68 KMT2A (0.44) LMNAKMT2AMEN1MAPTMAPK1
SCHEMBL25859551 0.68 MEN1 (0.39) KMT2AHPGDMEN1DYRK1ANLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227470-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER VANDERBILT UNIVERSITY 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227470-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER KRAS, NRAS, TP53 ADORA3 263/4885ADORA1 192/4885ADORA2A 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.